PROVECTUS RECEIVES FIFTH MEDICAL DEVICE PATENT

Provectus Pharmaceuticals, Inc. announced today that it has received its fifth patent for its medical device technologies (U.S. Patent 7,036,516), bringing the total patents received to-date in the U.S. to fifteen. The patent covers use of advanced laser technologies in the selective destruction of pigmented tissue, such as moles and pigmented skin cancers, including melanomas. Additional areas of applicability include selective destruction of hair follicles for hair reduction along with tattoo removal. Provectus Pharmaceuticals (http://www.pvct.com/pressrelease.html?article=20060502)